430P Efficacy of CDK4/6 inhibitors in BRCA-mutated HR+/HER2- metastatic breast cancer: Turkish Oncology Group (TOG) study
Makaleler > Tam Makale · 2026
Yazarlar: M. Seyyar, A. Kalem, A. Türkel, E. Uguztemur, A. Deligonul, I. Hacibekiroglu, A. Bayramgil, U. Oflazoglu, B. Karadurmus, N. Avci, I. Bilgetekin, B. Karabuga, T.K. Sahin, A.K. Disli, F. Ekinci, A.F. Akkus, H. Cinkir, I.N. Okten, D. Cabuk, H.C. Yildirim
ESMO Open, Uluslararası, Wos, 2026, cilt 11, ss 107453-107453
DOI: 10.1016/j.esmoop.2026.107453
Özet
Germline BRCA mutations (gBRCAm) occur in ∼5-10% of breast cancer patients, with approximately 60% presenting as HR+/HER2- disease. While CDK4/6 inhibitors have demonstrated significant efficacy in unselected HR+/HER2- metastatic breast cancer (MBC), emerging evidence suggests potentially reduced benefit in gBRCAm patients. A recent meta-analysis reported inferior PFS and OS for gBRCAm versus wild-type patients. This study evaluates real-world outcomes of CDK4/6 inhibitor therapy in gBRCAm HR+/HER2- MBC patients.